A radiation oncology clinician scientist devoted to building an inclusive clinical research program in an integrated academic satellite network in service to the National Cancer Institute

点击翻译按钮获取中文摘要

Project Summary This project, proposed by clinician scientist Stephen Chun, M.D. at the University of Texas, M.D. Anderson Cancer Center (MDACC) aims to expand the National Cancer Institute (NCI)-sponsored radiation oncology trial program in the Houston Area Location (HAL) integrated academic satellites and support his national leadership efforts with the NCI-sponsored cooperative groups. Since joining the MDACC faculty, Dr. Chun has led the establishment of the HAL radiation clinical trial program and is the Director of Radiation Oncology Clinical Research for the MDACC HALs. Under his leadership, there has been an unprecedented increase (1% in 2016 to 14% in 2021) in the proportion of HAL patients enrolled on radiation clinical trials. With the NCI-sponsored cooperative groups, Dr. Chun currently serves as national Principal Investigator (PI) of a high-profile NRG Oncology analysis, study champion of NRG/Alliance A082002, MDACC institutional PI of NRG-LU005, and has been a top enroller for NRG Oncology-RTOG 1308 that was previously in jeopardy for closure due to poor accrual. To achieve NCI-funded trial objectives in the MDACC HALs, Dr. Chun will spearhead the implementation and expansion of a translational biomarker program, neurocognitive testing capabilities for NCI-sponsored central nervous system (CNS) cancer trials, and the continuing medical education program on clinical research. Dr. Chun is passionate about addressing healthcare disparities and is committed to establish a workflow to track numbers of women and underrepresented minorities enrolled on clinical trials in the HALs, and independently scrutinize patient inclusion and exclusion criteria and factors among to reduce demographic disparities. In order to develop new research capabilities, Dr. Chun will join the leadership of the Protocol in a Day Workshop, which is responsible for developing MDACC investigator-initiated radiation trials, establish the radiation clinical research program at new and planned MDACC facilities, leverage artificial intelligence to capture more patients eligible for trials, and continue to develop concepts with the NCI-sponsored cooperative groups. He will commit a minimum of 20% of his effort (2.4 calendar months) to NCI-sponsored clinical research, and MDACC is committed to support Dr. Chun’s efforts and conduct of NCI-supported clinical trials. The primary objective of his career is to prioritize and expand institutional and NCI-sponsored trials in the MDACC HALs which aligns with this R50 funding mechanism as well as with the broader mission of NCI.